Lung cancer has become a leading cause of cancer-related death in the world. Patient
survival has improved with the introduction of new chemotherapy regimens and targeted …

Non–small-cell lung cancer (NSCLC) is one of the few diseases for which numerous
randomized clinical trials have compared best supportive care with chemotherapy. 1, 2 …

OBJECTIVE: Maintenance chemotherapy is a recently approved approach to the treatment
of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' …

Objectives The optimal treatment for recurrent non–small cell lung cancer (NSCLC) has not
been standardized. In this prospective cohort study, we evaluated post-recurrence survival …

The role of maintenance systemic therapy in the treatment of patients with advanced non–
small-cell lung cancer (NSCLC) has been a subject of debate for decades. Before the …

Although substantial progress has been made in the therapeutic options currently available
for patients with advanced non-small cell lung cancer (NSCLC), the overall survival profile …

Objectives Maintenance therapy for patients with advanced non-small-cell lung cancer
(NSCLC) is an increasingly hot topic in the field of clinical NSCLC research. This study …

Introduction Advanced non-small cell lung cancer (NSCLC) is a severe disease with
burdensome symptoms and traditionally poor outcomes. The treatment of advance disease …

Background The effect of palliative chemotherapy for non-small cell lung cancer (NSCLC) is
well established. Recently, immune checkpoint inhibitors have shown promising efficacy in …

Historically, first-line treatment of non-small-cell lung cancer (NSCLC) has been based on
giving a limited number of cycles of chemotherapy to achieve tumour response or stable …